Harvard Bioscience (NASDAQ:HBIO) Stock Rated Hold in New Coverage at Zacks Research

Equities research analysts at Zacks Research initiated coverage on shares of Harvard Bioscience (NASDAQ:HBIO) in a research note issued on Tuesday, Zacks reports. The firm set a “hold” rating on the medical instruments supplier’s stock.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings lowered Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. Benchmark boosted their price target on Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a research report on Wednesday, August 12th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $6.75.

Harvard Bioscience Price Performance

Shares of NASDAQ HBIO opened at $8.61 on Tuesday. The stock has a fifty day moving average price of $8.19 and a 200 day moving average price of $6.47. The company has a current ratio of 1.87, a quick ratio of 0.98 and a debt-to-equity ratio of 4.94. Harvard Bioscience has a 12-month low of $4.00 and a 12-month high of $9.10.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings data on Tuesday, August 11th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The company had revenue of $22.73 million for the quarter, compared to analysts’ expectations of $21.45 million. Harvard Bioscience had a negative return on equity of 33.13% and a negative net margin of 11.86%. On average, analysts expect that Harvard Bioscience will post -2.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Harvard Bioscience

An institutional investor recently bought a new stake in Harvard Bioscience stock. Meros Investment Management LP acquired a new position in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned approximately 4.02% of Harvard Bioscience at the end of the most recent reporting period. Institutional investors own 80.87% of the company’s stock.

More Harvard Bioscience News

Here are the key news stories impacting Harvard Bioscience this week:

• Neutral Sentiment: Sidoti forecasts a gradual improvement, with estimated losses of $2.44 per share in 2026 and $1.15 in 2027, followed by positive EPS of $0.43 in 2028. The outlook suggests a potential longer-term recovery, but the articles do not indicate that these estimates were revisions. MarketBeat Harvard Bioscience coverage
• Neutral Sentiment: CEO John Duke and CFO Mark Frost are scheduled to participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11. No new financial or operating information was disclosed in the announcement. Forum participation announcement

Harvard Bioscience Company Profile

Harvard Bioscience, Inc (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies.

The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.